Primavera Capital Group
VC Fund
Beijing, China
Primavera Capital Group is a China-based global investment firm. With offices located in Beijing and Hong Kong, Primavera manages both RMB and USD funds for leading institutions, corporations, and families in China and around the world.Primavera Capital Group was founded by Dr. Fred Hu, a renowned economist and successful investor, and aformer partner and Chairman of Greater China at Goldman Sachs Group.The firm currently has 30+ investment professionals with an outstanding track record. The team combines global capital market experience, deep industry knowledge, and a unique network of relationships with policy-makers and regulators as well as leading CEOs and entrepreneurs in the region and globally.Primavera Capital Group puts great emphasis on rigorous fundamental research. The firm undertakes sophisticated analysis on economies, industries and companies to generate investment ideas, identify attractive opportunities, and guide its investment decisions.Primavera Capital Group employs a flexible investment strategy of growth capital, buy-out and control, and special situations - restructuring, distressed, and turn-arounds, etc.
- Total investments:
- 93
- Last investment:
- Lead investor:
- 49%
- Fund size:
- $547M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Primavera Capital Group invests in
Stages Primavera Capital Group invests in
Countries Primavera Capital Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Round size
- Seed
- $1.5M–$15M
- Series A
- $12M–$290M
- Series B
- $25M–$585M
Investment Focus
Industry
- Artificial Intelligence 12 (13%)
- Software 10 (11%)
- Biotechnology 10 (11%)
- Health Care 9 (10%)
- Information Technology 8 (9%)
Stage
- Series A 16 (17%)
- Seed 10 (11%)
- Series B 10 (11%)
- Series D 10 (11%)
- Private Equity 10 (11%)
Country
- China 52 (56%)
- United States 8 (9%)
- Hong Kong 3 (3%)
- Singapore 2 (2%)
- Portugal 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Lin
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Fred Hu
Founder, Chairman & CEO
|
Founder, Chairman & CEO | Total investments: 0 | Find email | |
Johnny Zou
Executive Director
|
Executive Director | Total investments: 2 | Find email | |
Dapeng Zhu
Managing Director
|
Managing Director | Total investments: 1 | Find email | |
William Wang
Founding Partner
|
Founding Partner | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Xingyun is a semiconductor company focused on building software-friendly, high-memory-specification large-scale model inference chips, driving large-scale models to higher quality and lower cost, and addressing computational power costs. | $119.5M / Venture - Series Unknown / Sep 21, 2026 | ||
| Anew Labs is an AI drug discovery company that combines generative models with experimental science. | $290M / Series A / Sep 16, 2026 | ||
VAST
|
VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $446.4M / Series B / Sep 01, 2026 | |
| Kling AI is an AI-powered creative studio for creating imaginative images and videos, based on state-of-the-art generative AI methods. | $2.8B / Venture - Series Unknown / Jul 01, 2026 | ||
|
VAST
|
VAST is an artificial intelligence business that develops and manufactures general-purpose 3D big models. Its goal is to develop a popular 3D content production tool, a 3D user-generated content platform, and utilize 3D space to enhance user experience. | $200M / Series A / Jun 01, 2026 | |
| Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields. | $40M / Series B / May 12, 2026 | ||
| Gongji Technology is an idle computing power sharing platform that combines distributed computing power with leading scheduling techniques to address elastic computing power requirements. | $14.7M / Seed / May 08, 2026 | ||
| Xingyun is a semiconductor company focused on building software-friendly, high-memory-specification large-scale model inference chips, driving large-scale models to higher quality and lower cost, and addressing computational power costs. | $58.6M / Series A / Apr 17, 2026 | ||
|
Yuansheng Intelligent Robotics
|
Yuansheng Intelligent Robotics is a field of intelligent robotics technology and is committed to developing core products | $14.7M / Venture - Series Unknown / Apr 15, 2026 | |
|
ProLens Interactive Technology
|
ProLens Interactive Technology is building a high-efficiency conversion link from low-cost computing power investment to the accumulation of high-premium compliant digital assets, redefining the next generation of interactive entertainment experience. | Angel / Mar 24, 2026 | |
| See all 93 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Primavera Capital Group invest in?
Primavera Capital Group invests primarily in Artificial Intelligence, Software and Biotechnology startups, most often at Series A and Seed stage. Most of the 93 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Primavera Capital Group's check size?
Primavera Capital Group typically joins rounds of $1.5M–$15M at Seed, $12M–$290M at Series A and $25M–$585M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Primavera Capital Group participates in.
How do I contact Primavera Capital Group?
Public channels for Primavera Capital Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Primavera Capital Group?
The team at Primavera Capital Group includes David Lin (Managing Director), Fred Hu (Founder, Chairman & CEO) and Johnny Zou (Executive Director), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
